00:12 , Jul 19, 2019 |  BC Extra  |  Company News

July 18 Company Quick Takes: Mallinckrodt, Silence in RNAi deal; plus Pear, Blueprint and more

Mallinckrodt licenses RNAi candidate from Silence  Mallinckrodt plc (NYSE:MNK) obtained an exclusive, worldwide license to C3-targeted RNAi therapy SLN500 from Silence Therapeutics plc (LSE:SLN), plus options to license up to two additional complement-targeted preclinical candidates....
23:27 , Jul 15, 2019 |  BC Extra  |  Financial News

AI play Recursion raises $121M to expand into new drug discovery

Recursion’s $121 million series C round will allow the company to expand its artificial intelligence-based drug repurposing platform for rare diseases and develop capabilities for new drug discovery while pushing its pair of lead programs...
21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
20:45 , Jul 11, 2019 |  BC Extra  |  Company News

Management tracks: President of Lilly BioMedicines steps down to lead Kite; plus Alnylam, GSK, and more

Christi Shaw, SVP and president of Lilly BioMedicines at Eli Lilly and Co. (NYSE:LLY), will step down at the end of August to serve as CEO of the Kite Pharma unit of Gilead Sciences Inc....
00:27 , Jul 11, 2019 |  BC Extra  |  Company News

July 10 Company Quick Takes: I-Mab licenses MacroGenics mAb; plus Mirati-Novartis, Jazz-Redx, Sanofi, Horizon and more

I-Mab gains China rights to enoblituzumab I-Mab Biopharma (Shanghai, China) gained exclusive rights to enoblituzumab from MacroGenics Inc. (NASDAQ:MGNX) in China, Hong Kong, Macao and Taiwan for $15 million up front. MacroGenics is eligible for...
11:30 , Jul 9, 2019 |  BioCentury  |  Finance

Revolution raises $100M to build out Ras pipeline, explore SHP-2 combos

Following this year’s ASCO fervor around KRAS inhibitors, Revolution Medicines has raised $100 million in a series C round to advance its portfolio of Ras pathway inhibitors, including its own KRAS G12C inhibitor. The financing,...
21:06 , Jul 8, 2019 |  BC Extra  |  Politics & Policy

Zerhouni warns against driving Chinese scientists out of the U.S.

Overreaction to concerns about Chinese threats to the integrity of American science could create an exodus of talented researchers that would cause lasting harm to U.S. national interests, former NIH Director Elias Zerhouni warned in...
15:53 , Jul 3, 2019 |  BioCentury  |  Emerging Company Profile

Kymera: a systematic approach to protein degradation

With a computational drug discovery platform and a proprietary library of E3 ligases and binders, Kymera believes it can accelerate the discovery and development of protein degraders. Protein degradation is entering the mainstream as a...
01:58 , Jun 29, 2019 |  BioCentury  |  Finance

Biotech backs down in 2Q19

In a reversal from 1Q19, biotech stocks across all market cap tiers fell in the second quarter, leading to a total loss of $22.3 billion. However, the year-to-date change in market cap remains well in...
00:47 , Jun 29, 2019 |  BioCentury  |  Finance

All eyes on new modality launches, cancer and rare disease data in 3Q19

While the typical summer lull means fewer catalysts in the third quarter, investors will be keeping a close eye on launches of new modality drugs. Of special interest to multiple buysiders is the launch of...